Nuhad K. Ibrahim

Nov 16, 2023 | nature.com | Nancy Lin |Solmaz Sahebjam |Nuhad K. Ibrahim

AbstractThe PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Primary analysis confirmed CNS objective response rate (ORR) was 11% (95% confidence interval [CI]: 3–25); clinical benefit rate (CBR) was 68% (4 months) and 51% (6 months).

Jul 5, 2023 | fal.cn | Nuhad K. Ibrahim

Nuhad K. Ibrahim, professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the investigation of eftilagimod alpha (IMP321) plus in hormone receptor (HR)–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial (NCT05747794). Eftilagimod alpha is a soluble LAG-3 agent known to have a synergistic effect with chemotherapy.

Jul 5, 2023 | onclive.com | Nuhad K. Ibrahim

Nuhad K. Ibrahim, professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the investigation of eftilagimod alpha (IMP321) plus in hormone receptor (HR)–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial (NCT05747794). Eftilagimod alpha is a soluble LAG-3 agent known to have a synergistic effect with chemotherapy.